Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled Study to Evaluation the Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli) in a Population Aged 3 Months-50 Years Old

NCT06314880 is registered in ClinicalTrials.gov with Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd as lead sponsor.

NCT NCT06314880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06314880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled Study to Evaluation the Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli) in a Population Aged 3 Months-50 Years Old
Lead sponsor
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
July 22, 2023
Completion date
December 30, 2024
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers